Magnesium Sulfate
Key Points
- Magnesium sulfate is the drug of choice for seizure prevention in preeclampsia (eclampsia prophylaxis) and for treating eclamptic seizures.
- Also used as a tocolytic (suppresses preterm uterine contractions) and for fetal neuroprotection at 24–31 6/7 weeks’ gestation.
- In intrapartum preterm labor care, magnesium sulfate may be used short term to create a corticosteroid window when imminent birth risk is high.
- Loading dose: 4–6 g IV over 20–30 minutes; maintenance: 1–4 g/hour continuous infusion.
- Mandatory pre-dose assessment: patellar reflexes present, respirations ≥16 breaths/min, urine output ≥30 mL/hour.
- Antidote: calcium gluconate 1 g IV — must be kept at the bedside at all times.
- Because magnesium sulfate is high-alert, independent double-check of order, dose, and pump settings is required before and during infusion.
Mechanism of Action
The precise mechanism for tocolysis is not fully established. Magnesium sulfate is thought to relax uterine smooth muscle by decreasing the release of acetylcholine at the motor nerve terminal and blocking neuromuscular transmission. As a CNS depressant and peripheral vasodilator, magnesium reduces neuronal excitability and suppresses seizure activity in eclampsia.
For fetal neuroprotection, magnesium sulfate protects the developing brain from intraventricular hemorrhage by stabilizing cerebral blood flow and reducing the inflammatory cascade associated with preterm hypoxia.
Indications
| Indication | Gestational Context |
|---|---|
| Eclampsia prophylaxis (seizure prevention) | Preeclampsia, any gestational age |
| Eclampsia treatment (active seizures) | Any gestational age |
| Tocolysis (preterm labor suppression) | <34 weeks’ gestation |
| Fetal neuroprotection | 24–31 6/7 weeks’ gestation |
Contraindications: renal dysfunction (magnesium is renally cleared), myasthenia gravis, significant cardiac disease.
Dosing
- Loading dose: 4–6 g IV administered over 20–30 minutes
- Maintenance infusion: 1–4 g/hour continuous IV infusion
- Continue infusion through labor and for 24 hours postpartum (eclampsia prophylaxis)
- Administer via infusion pump only — never bolus the maintenance dose
Nursing Assessment
NCLEX Focus
The three mandatory assessments before each dose: (1) patellar reflexes present, (2) respirations ≥16/min, (3) urine output ≥30 mL/hour. If any one is absent or below threshold, hold the dose and notify the provider immediately.
Pre-dose and ongoing assessment:
- Patellar reflexes: must be present; loss of deep tendon reflexes is the first sign of magnesium toxicity
- Respirations: must be ≥16 breaths/minute; magnesium causes respiratory depression at toxic levels
- Urine output: must be ≥30 mL/hour; renal clearance of magnesium is impaired by oliguria
- Serum magnesium level (if available): therapeutic range is protocol-dependent (commonly about 2.5–7.5 mEq/L in obstetric pathways)
Toxicity progression (correlates with serum level):
- Loss of deep tendon reflexes (first sign) → respiratory depression → cardiac arrest
- Because severe toxicity can progress rapidly, any emerging hyporeflexia or respiratory decline should trigger immediate infusion hold and antidote readiness.
Nursing Interventions
Administration:
- Use infusion pump; verify rate at each assessment
- Perform independent second-nurse verification of order, dose calculation, and infusion-pump settings per high-alert policy.
- Have calcium gluconate 1 g IV drawn up or immediately accessible at bedside
- Monitor continuous electronic fetal monitoring — magnesium sulfate decreases baseline fetal heart rate variability (expected effect, not a sign of fetal distress)
Side effect management:
- Flushing, diaphoresis, headache, nausea, muscle weakness — educate client that these are expected
- Blurred vision and hyporeflexia — indicate approaching therapeutic ceiling; reassess frequently
- Hypotension — monitor blood pressure every 15–30 minutes
- Prolonged maternal exposure (more than about 5 to 7 days) may increase fetal bone-related adverse effects and neonatal depression risk; avoid unnecessary prolonged infusion.
Eclampsia emergency response:
- If seizure occurs: call for help, position on left side, protect airway, do not restrain or insert objects in mouth, administer magnesium sulfate bolus as ordered
- Continuous fetal monitoring during and after seizure
Toxicity reversal:
- Calcium gluconate 1 g IV over 3 minutes — antagonizes magnesium at neuromuscular junction
- Oxygen, ventilatory support if respiratory depression
- After delivery, monitor newborn for hypotension, hyporeflexia, and respiratory depression; prepare neonatal resuscitation support if needed.
Magnesium Toxicity
Absent patellar reflexes, respiratory rate <12 breaths/min, or urine output <25 mL/hour requires immediate cessation of infusion and administration of calcium gluconate 1 g IV. Have resuscitation equipment available.
Related Concepts
- preeclampsia — Primary indication for magnesium sulfate; comprehensive nursing management of hypertensive pregnancy disorders.
- tocolytics — Magnesium sulfate as one agent in the class of preterm labor suppressants.
- fhr-and-uc-intervention-framework — Expected FHR variability reduction with magnesium; fetal monitoring interpretation.
- conditions-limited-to-pregnancy — Eclampsia and preterm labor as pregnancy-specific complications.
- postpartum-hemorrhage — Magnesium infusion continued postpartum; monitoring during fourth stage.
- calcium-balance-disorders — Calcium gluconate as the physiologic antidote; calcium–magnesium antagonism.
Self-Check
- A client receiving magnesium sulfate has a respiratory rate of 10 breaths/min and absent patellar reflexes. What is the priority nursing action?
- Why does magnesium sulfate decrease fetal heart rate variability, and does this require intervention?
- A client with preeclampsia is transitioning to the postpartum unit. How long should the magnesium sulfate infusion continue, and why?